Andrea Henrich
Allschwil, BL 4123, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I data.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: November 25, 2024
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.
Journal: British journal of clinical pharmacology
Published: September 05, 2024
Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.
Journal: Metabolism: clinical and experimental
Published: September 27, 2022
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
Journal: Clinical drug investigation
Published: July 11, 2021
Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 26, 2021
A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker.
Journal: Clinical pharmacology and therapeutics
Published: September 21, 2020
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: April 21, 2020
The Case for an Unblinded Modeler in Early Clinical Development.
Journal: Journal of clinical pharmacology
Published: May 22, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026